We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Teladoc Health, Inc. (TDOC - Free Report) , Albireo Pharma, Inc. and The Joint Corp. (JYNT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
What's in Store for Teladoc's (TDOC - Free Report) Q4 Earnings?
Teladoc Health, Inc. is scheduled to release fourth-quarter 2021 results on Feb 22, 2022, after the market closes.
Q4 Earnings & Revenue Expectations
The Zacks Consensus Estimate for Teladoc Health’s fourth-quarter loss of 59 cents per share indicates a deterioration from the loss of 27 cents reported in the year-ago quarter. The consensus estimate for sales of $547 million suggests a 42.8% rise from the year-ago period’s reported figure of $383 million.
TDOC is expected to have gained from substantial revenue growth and an uptick in visits, partly offset by escalating costs in the to-be-reported quarter.
Revenues are likely to have gained from higher Access Fee revenues. The increase in access fee revenues might have been primarily led by the acquisitions of Livongo and InTouch Health, both of which generate a chunk of revenues from the subscription access fees and growth in direct-to-consumer mental health, which is sold on a subscription basis.
TDOC is also well-poised for growth owing to virtual care business. Given the current situation, demand for virtual care or telehealth care is here to stay. For the fourth quarter, management expected revenues of $536-$546 million (per the last earnings call).
The same is likely to indicate an upside of 40-42% growth from the year-ago quarter’s reported figure. Management also declared that it expects total paid membership in the band of 52.5-53.5 million. It also projects total visits of 3.9-4.1 million in the to-be-reported quarter.
Per management’s fourth-quarter guidance, adjusted EBITDA is anticipated in the range of $69-$74 million.
Total expenses are expected to have escalated in the quarter, primarily due to higher advertising and marketing, sales, technology and development, legal and regulatory, acquisition and integration-related costs as well as general and administrative expenses.
Earnings Surprise History
Teladoc Health’s bottom line beat estimates in two of the last four quarters (missing the mark on the remaining two occasions), the average surprise being 23.34%.
Our proven model predicts an earnings beat for Teladoc Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Teladoc Health has an Earnings ESP of +9.83%.
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free.Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp
For Immediate Release
Chicago, IL – February 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Teladoc Health, Inc. (TDOC - Free Report) , Albireo Pharma, Inc. and The Joint Corp. (JYNT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
What's in Store for Teladoc's (TDOC - Free Report) Q4 Earnings?
Teladoc Health, Inc. is scheduled to release fourth-quarter 2021 results on Feb 22, 2022, after the market closes.
Q4 Earnings & Revenue Expectations
The Zacks Consensus Estimate for Teladoc Health’s fourth-quarter loss of 59 cents per share indicates a deterioration from the loss of 27 cents reported in the year-ago quarter. The consensus estimate for sales of $547 million suggests a 42.8% rise from the year-ago period’s reported figure of $383 million.
TDOC is expected to have gained from substantial revenue growth and an uptick in visits, partly offset by escalating costs in the to-be-reported quarter.
Let’s see how things have shaped up prior to the fourth-quarter earnings announcement.
Factors to Note
Revenues are likely to have gained from higher Access Fee revenues. The increase in access fee revenues might have been primarily led by the acquisitions of Livongo and InTouch Health, both of which generate a chunk of revenues from the subscription access fees and growth in direct-to-consumer mental health, which is sold on a subscription basis.
TDOC is also well-poised for growth owing to virtual care business. Given the current situation, demand for virtual care or telehealth care is here to stay. For the fourth quarter, management expected revenues of $536-$546 million (per the last earnings call).
The same is likely to indicate an upside of 40-42% growth from the year-ago quarter’s reported figure. Management also declared that it expects total paid membership in the band of 52.5-53.5 million. It also projects total visits of 3.9-4.1 million in the to-be-reported quarter.
Per management’s fourth-quarter guidance, adjusted EBITDA is anticipated in the range of $69-$74 million.
Total expenses are expected to have escalated in the quarter, primarily due to higher advertising and marketing, sales, technology and development, legal and regulatory, acquisition and integration-related costs as well as general and administrative expenses.
Earnings Surprise History
Teladoc Health’s bottom line beat estimates in two of the last four quarters (missing the mark on the remaining two occasions), the average surprise being 23.34%.
Teladoc Health, Inc. price-eps-surprise | Teladoc Health, Inc. Quote
What Our Model Says
Our proven model predicts an earnings beat for Teladoc Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Teladoc Health has an Earnings ESP of +9.83%.
Zacks Rank: Teladoc Health currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other stocks worth considering from the medical space with the perfect mix of elements to surpass estimates in their upcoming releases.
Albireo Pharma, Inc. has an Earnings ESP of +2.84% and is Zacks #3 Ranked, currently. ALBO will report its fourth-quarter results on Feb 24.
The Joint Corp. an Earnings ESP of +6.67% and a Zacks Rank #2 at present. JYNT will deliver its fourth-quarter results on Feb 24.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free.Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.